Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Free Cash Flow (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Free Cash Flow for 4 consecutive years, with -$55.8 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 30.42% to -$55.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$194.1 million through Dec 2025, down 36.58% year-over-year, with the annual reading at -$194.2 million for FY2025, 36.67% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$55.8 million at Centessa Pharmaceuticals, up from -$58.5 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$21.4 million in Q3 2024, with the low at -$60.1 million in Q2 2022.
  • Average Free Cash Flow over 4 years is -$43.6 million, with a median of -$43.4 million recorded in 2023.
  • Peak annual rise in Free Cash Flow hit 44.67% in 2025, while the deepest fall reached 173.29% in 2025.
  • Over 4 years, Free Cash Flow stood at -$52.2 million in 2022, then surged by 40.48% to -$31.1 million in 2023, then crashed by 37.72% to -$42.8 million in 2024, then crashed by 30.42% to -$55.8 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$55.8 million, -$58.5 million, and -$22.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.